
Verdiva Bio Highlights Obesity Drug Research at ADA 2026
Verdiva Bio Highlights Promising Preclinical Obesity Drug Candidates at ADA 2026 Verdiva Bio, a clinical-stage biotechnology company focused on developing scalable, once-weekly oral therapies for obesity, has unveiled new preclinical…












